AI assistant
Processa Pharmaceuticals, Inc. — Director's Dealing 2023
Jan 4, 2023
35172_dirs_2023-01-04_12c439df-ec96-4aeb-b79a-9f4f56ea34fa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-12-31
Reporting Person: Young David (Director, President & CEO, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | Restricted Stock Units | $0 | A | 25350 | Acquired | Common Stock (25350) | Direct | |
| 2023-01-01 | Restricted Stock Units | $0 | A | 24030 | Acquired | Common Stock (24030) | Direct |
Footnotes
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the lessee's common stock upon the earliest of termination of employment, the third anniversary of the award date, a change of control, or the reporting person's death. These restricted stock units vest on date of grant.
F2: Each restricted stock units represents a contingent right to receive one share of the issuer's common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death.